TABLE OF CONTENTS
Detailed Table of Contents
1. Executive Summary
1.1Market Overview
1.2Key Findings
1.3Growth Opportunities
1.4Competitive Summary
2. Research Scope and Methodology
2.1Market Definition and Boundaries
2.2Commercial Dose versus Captive Production
2.3Bottom-Up Dose-Volume Model
2.4Supplier Revenue Reconciliation
2.5Assumptions and Sensitivity
3. Market Dynamics
3.1PET Procedure Demand
3.2Tracer Commercialization
3.3Production and Logistics Constraints
3.4Reimbursement and Regulatory Environment
3.5Investment Opportunities
4. Market Analysis by Radiotracer
4.118F-FDG
4.2Other 18F Tracers
4.368Ga Tracers
4.4Other PET Tracers
4.5Leading and Fastest-Growing Tracers
5. Market Analysis by Supply Model
5.1Commercial Radiopharmacy Networks
5.2Contract Manufacturing
5.3Hospital-Affiliated External Supply
5.4Market Positioning
6. Market Analysis by Application
6.1Oncology
6.2Neurology
6.3Cardiology
6.4Other Applications
7. Market Analysis by Customer
7.1Hospitals
7.2Independent Imaging Centers
7.3Academic and Research Institutions
8. Regional Market Analysis
8.1North America: United States, Canada
8.2Europe: Germany, France, United Kingdom, Italy, Spain, Rest of Europe
8.3Asia Pacific: China, Japan, India, South Korea, Australia, Rest of Asia Pacific
8.4Latin America: Brazil, Mexico, Rest of Latin America
8.5Middle East & Africa: GCC, South Africa, Rest of MEA
9. Competitive Landscape
9.1Supplier Positioning
9.2Siemens Healthineers Radiopharma
9.3Cardinal Health
9.4SOFIE Biosciences
9.5Other Regional Suppliers
9.6Facility Expansion, Acquisitions and Partnerships
10. Appendix
10.1Terminology
10.2Dose and Tracer Definitions
10.3Data Sources
10.4Forecast Methodology